Animal Efficacy Rule Will Be “Flexible” About Species Needed – CBER’s Zoon
Executive Summary
FDA will exercise more flexibility in the number of animal species required for testing before approval of counter-terrorism products under the final animal efficacy rule, Center for Biologics Evaluation & Research Director Kathy Zoon, PhD, said
You may also be interested in...
FDA Animal Efficacy Rule Drops Superiority Requirement For New Agents
FDA's final rule allowing drug approvals based on animal efficacy studies will permit more than one drug to be approved for an indication without a clear demonstration of superiority over existing products
FDA Animal Efficacy Rule Drops Superiority Requirement For New Agents
FDA's final rule allowing drug approvals based on animal efficacy studies will permit more than one drug to be approved for an indication without a clear demonstration of superiority over existing products
Anthrax Post-Exposure Drugs Need Extensive Marketing History – Draft Guidance
Drugs should have broad postmarketing experience before sponsors pursue an indication for post-exposure anthrax, a draft guidance from FDA's Center for Drug Evaluation & Research states